IGHE and asthma: Conversely, based on the results of clinical trials such as the EXTRA study [122], the ERS/ATS guidelines for the management of severe asthma recommend using a FeNO cut-off of ≥19.5 ppb to identify patients with a higher probability of benefitting from anti-IgE treatment [162].